Mirdametinib Shows Improved ORR Over Time in NF1-Associated Symptomatic Plexiform Neurofibroma
OncLive,
What was the design of the ReNeu trial examining mirdametinib in NF1-PN? The multicenter, single-arm ReNeu study enrolled…
Mirdametinib Use in NF1-Associated PNs Balances Efficacy and QOL Considerations
OncLive,
Rene Y. McNall-Knapp, MD Multidisciplinary collaboration is key for addressing both disease burden and symptoms in patients…
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
AJMC,
The FDA recently approved mirdametinib (Gomekli; SpringWorks Therapeutics) to treat adults and children aged 2 and older with…
Gomekli Approved for NF1-Associated Plexiform Neurofibromas
Neurology Advisor ,
The Food and Drug Administration (FDA) has approved Gomekli™ (mirdametinib) for the treatment of adult and pediatric patients…